Aptahem – a Swedish biotech aiming to win the race against sepsis

In the fight to save a person affected by sepsis every second counts – each hour that passes increases the risk of death with 8 percent. It is literally a race against time, a race that the healthcare services all but too often lose. However, Swedish biotech Aptahem are developing an emergency treatment to better the odds and prevent the massive organ failure that leads to the deaths of millions of sepsis patients globally each year.